Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: docetaxel and epirubicin|DRUG: docetaxel and epirubicin plus endostatin
Sponsor: Xijing Hospital